Extracellular Vesicles:

Powerful Small Messengers

Extracellular vesicles (EVs) are small particles secreted by all cells, each carrying a complex cargo of proteins, lipids and nucleic acids. The encapsulation of biological molecules within a lipid bilayer enables the delivery of critical signals to distant cells and tissues, turning these vesicles into an elite method of cellular communication.

Due to their role as biological messengers, EVs have gained attention in recent years, for their potential as therapeutic agents. Several companies and research groups are actively investigating EVs, employing a variety of source materials, production methods, and modification strategies. Overall, EV-based therapies hold promise for treating a range of condicions, including for cardiovascular1, neurological2 or rheumatoid3 , and inflammatory diseases4-6  .

Discover how Exogenus Therapeutics is pioneering the use of a unique birth material to produce Exo-101, a solution of small but powerful vesicles packed with a cocktail of therapeutic molecules designed by Nature to address a wide array of health challenges.

 

References

de Abreu, R. C. et al. Native and bioengineered extracellular vesicles for cardiovascular therapeutics. Nat. Rev. Cardiol. 17, 685–697 (2020).

Zhang, Z. G., Buller, B. & Chopp, M. Exosomes – beyond stem cells for restorative therapy in stroke and neurological  injury. Nat. Rev. Neurol. 15, 193–203 (2019).

Malda, J., Boere, J., van de Lest, C. H. A., van Weeren, P. R. & Wauben, M. H. M. Extracellular vesicles — new tool for joint repair and regeneration. Nature reviews. Rheumatology 12, 243–249 (2016).

Robbins, P. D. & Morelli, A. E. Regulation of immune responses by extracellular vesicles. Nat. Rev. Immunol. 14, 195–208 (2014).

Andaloussi, S. EL, Mäger, I., Breakefield, X. O. & Wood, M. J. A. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat. Rev. Drug Discov. 12, 347–357 (2013).

Buzas, E. I., György, B., Nagy, G., Falus, A. & Gay, S. Emerging role of extracellular vesicles in inflammatory diseases. Nat. Rev. Rheumatol. 10, 356–364 (2014).

EXO-101

Exo-101 is produced from umbilical cord blood mononuclear cells, using a proprietary process. Our optimized process, combining ultrafiltration and chromatography, allows for standardization, large-scale manufacturing and GMP compliance. 

1. Blood Collection

2. Cells Separation

3.Tailored Stimuli

4. Exo-101 Purification

5. Pooling

6. Final Formulation

To learn more about Exo-101, explore our publications.